COMMUNIQUÉS West-GlobeNewswire

STRATA Skin Sciences Announces COFEPRIS Clearance of TheraClear® in Mexico and First Commercial Placements
28/10/2025
HORSHAM, Pa., Oct. 28, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a global leader in in-office dermatologic technologies for the treatment of skin conditions such as acne, psoriasis, and [...]
Glucotrack, Inc. Reminds Shareholders to Vote
28/10/2025
The Special Meeting of Shareholders held on October 31, 2025 Shareholders vote on Equity Purchase Agreement with Sixth Borough Capital Fund RUTHERFORD, N.J., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: [...]
Nautilus Biotechnology Reports Third Quarter 2025 Financial Results
28/10/2025
SEATTLE, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the third [...]
CervoMed Strengthens Board with Appointment of Life Sciences Business Strategy Leader David Quigley
28/10/2025
Mr. Quigley most recently led McKinsey & Company’s Private Capital practice and previously led various Life Sciences practices at the firm Appointment adds deep business strategy, transactional, and commercial [...]
AssistRx Named a Winner of the Orlando Sentinel Media Group’s Central Florida Top Workplaces 2025 Award
28/10/2025
Healthcare technology and patient solutions provider recognized as a Central Florida top employer for fifth consecutive year ORLANDO, Fla., Oct. 28, 2025 (GLOBE NEWSWIRE) -- AssistRx , the advanced therapy initiation [...]
R1 Welcomes Estelle Barnes to Lead Enterprise Customer Engagement and Partnerships
28/10/2025
MURRAY, Utah, Oct. 28, 2025 (GLOBE NEWSWIRE) -- R1 (“R1” or the “Company”), the leader in healthcare revenue management, today announced the appointment of Estelle Barnes as the leader of R1’s Enterprise Customer [...]
ORYZON Strengthens Regulatory Strategy with the Appointment of Dr. Iman Barilero as Senior Advisor for Regulatory Affairs
28/10/2025
To enhance and accelerate regulatory dialogue with the FDA To provide strategic guidance across clinical development programs To bring deep expertise in CNS and immuno-oncology MADRID and CAMBRIDGE, Mass., Oct. 28, 2025 [...]
Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer
28/10/2025
Karen Smith, MD, PhD, MBA, LLM, joins with over 25 years of global pharma and biotech experience, having contributed to more than 20 regulatory approvals Dr Smith's appointment will accelerate Step Pharma's ‘pipeline in [...]
SparingVision Doses First Patient with SPVN20 for Advanced Retinitis Pigmentosa in NYRVANA Trial
28/10/2025
SparingVision Doses First Patient with SPVN20 for Advanced Retinitis Pigmentosa in NYRVANA Trial SPVN20 aims to restore visual acuity and aspects of color vision by creating an alternative light-signaling cascade in [...]
Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study
28/10/2025
Study met primary and secondary endpoints Paridiprubart demonstrated a relative reduction in the risk of death of 25% Treatment provided patients with clinically meaningful improvement in survival and recovery [...]
BioNTech to Host Innovation Series R&D Day on November 11, 2025
28/10/2025
MAINZ, Germany, October 28 , 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), will host an edition of the Company’s Innovation Series R&D Day at 09:00 a.m. Eastern Standard Time (3: [...]
Evidence Against Evidence: CERN-IEEE FPGA vs. Crosetto 3D-Flow, a Breakthrough Invention Recognized 32 Years Ago That Could Have, and Can Still, Save Billions of Euros and Millions of Lives
28/10/2025
Science vs. Consensus: An urgent call to CERN, IEEE, and the scientific community to engage with verifiable evidence, fulfill scientific duty, and resolve contradictions based on the laws of nature, not institutional [...]
Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution
28/10/2025
– ARCALYST ® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth – – ARCALYST 2025 expected net product revenue raised to $670 - $675 million – – KPL-387 granted Orphan [...]
Context Therapeutics to Participate in Upcoming Investor Conferences
28/10/2025
PHILADELPHIA, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid [...]
Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance
28/10/2025
Revenue of $189 million, year-over-year increase of 22% as reported and 18% organic with double-digit reported growth across all franchises Orders increased sequentially and greater than 20% year-over-year Increasing [...]
TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI
28/10/2025
NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has completed in the randomized cohort of the Phase 3 ENHANCE trial evaluating a consolidated Day 1 and [...]
Cronos Brings Back Popular, Limited-Edition Spinach® Green Apple-Flavored Products for the Fall Season
28/10/2025
TORONTO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos”), an innovative global cannabinoid company, announced today that it is welcoming back its limited-edition Caramel Green [...]
Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
28/10/2025
NEW HAVEN, Conn., Oct. 28, 2025 (GLOBE NEWSWIRE) -- WHAT: Invivyd, Inc. (Nasdaq: IVVD) is hosting the previously announced live webcast to present an overview of the company’s REVOLUTION clinical program, Invivyd’s [...]
Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025
28/10/2025
WATERTOWN, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological [...]

Pages